Online inquiry

IVTScrip™ mRNA-Anti-FOLR1, MORAb-003(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12126MR)

This product GTTS-WQ12126MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets FOLR1 gene. The antibody can be applied in Ovarian Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000802.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2348
UniProt ID P15328
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FOLR1, MORAb-003(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ12126MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4543MR IVTScrip™ mRNA-Anti-PDCD1, BMS-936558(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BMS-936558
GTTS-WQ15707MR IVTScrip™ mRNA-Anti-S, VIR-7831(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA VIR-7831
GTTS-WQ8896MR IVTScrip™ mRNA-Anti-IGHE, IGE25(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IGE25
GTTS-WQ6800MR IVTScrip™ mRNA-Anti-ERBB2, DS-8201(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA DS-8201
GTTS-WQ4147MR IVTScrip™ mRNA-Anti-PDCD1, BI-754091(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BI-754091
GTTS-WQ1239MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, ABT-165(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABT-165
GTTS-WQ11516MR IVTScrip™ mRNA-Anti-FGFR3, MFGR1877S(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MFGR1877S
GTTS-WQ15618MR IVTScrip™ mRNA-Anti-TNFRSF13C, VAY-736(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA VAY-736
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW